Revenue remains highly erratic, fluctuating between $7.0M and $28.9M over the last ten quarters, while R&D costs consistently dwarf top-line results, as evidenced by the $80.7M spent in 2026Q1.
| Sales/Revenue | 66.09M | 67.67M | 57.88M | 36.27M | 52.12M | 33.05M | 57.99M | 43.1M | 30.43M | 26.12M | 16.48M | 6.04M | 0 |
| Revenue Growth % | 45.04% | 16.92% | 59.55% | -30.4% | 57.69% | -43.01% | 34.55% | 41.63% | 16.53% | 58.49% | 172.65% | - | - |
| Cost of Goods Sold | 87.17M | 15.92M | 10.29M | 8.98M | 7.57M | 6.89M | 150.41M | 108.41M | 89.11M | 67.65M | 31.84M | 11.17M | 1.66M |
| COGS % of Revenue | - | 23.53% | 17.77% | 24.74% | 14.53% | 20.85% | 259.35% | 251.52% | 292.81% | 259.02% | 193.22% | 184.81% | - |
| Gross Profit | -21.07M | 51.75M | 47.59M | 27.3M | 44.55M | 26.16M | -92.41M | -65.31M | -58.68M | -41.53M | -15.36M | -5.13M | -1.66M |
| Gross Margin % | -31.89% | 76.47% | 82.23% | 75.26% | 85.47% | 79.15% | -159.35% | -151.52% | -192.81% | -159.02% | -93.22% | -84.81% | - |
| Gross Profit Growth % | - | 8.73% | 74.34% | -38.72% | 70.28% | 128.31% | -41.5% | -11.3% | -41.3% | -170.36% | -199.67% | -209.26% | - |
| Operating Expenses | 399.64M | 492.74M | 581.86M | 542.59M | 502.71M | 294.01M | 44.17M | 41.06M | 121.3M | 95.67M | 48.64M | 19.45M | 12.65M |
| OpEx % of Revenue | - | 728.14% | 1005.33% | 1495.77% | 964.51% | 889.52% | 76.16% | 95.26% | 398.58% | 366.32% | 295.15% | 321.86% | - |
| Selling, General & Admin | 141.43M | 119.8M | 125.83M | 116.5M | 90.31M | 71.1M | 44.17M | 41.06M | 32.19M | 28.02M | 16.8M | 8.28M | 3.57M |
| SG&A % of Revenue | - | 177.03% | 217.41% | 321.15% | 173.26% | 215.1% | 76.16% | 95.26% | 105.77% | 107.31% | 101.94% | 137.04% | - |
| Research & Development | 361.17M | 388.86M | 466.31M | 435.07M | 419.98M | 229.81M | 150.41M | 108.41M | 89.11M | 67.65M | 31.84M | 11.17M | 10.74M |
| R&D % of Revenue | - | 574.63% | 805.69% | 1199.36% | 805.78% | 695.27% | 259.35% | 251.52% | 292.81% | 259.02% | 193.22% | 184.81% | - |
| Other Operating Expenses | -3M | -15.92M | -10.29M | -8.98M | -7.57M | -6.89M | -150.41M | -108.41M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -420.71M | -440.99M | -534.26M | -515.29M | -458.16M | -267.85M | -136.58M | -106.37M | -90.87M | -69.56M | -32.16M | -13.41M | -5.23M |
| Operating Margin % | -636.56% | -651.67% | -923.1% | -1420.51% | -879.04% | -810.37% | -235.51% | -246.78% | -298.58% | -266.32% | -195.15% | -221.86% | - |
| Operating Income Growth % | - | 17.46% | -3.68% | -12.47% | -71.05% | -96.11% | -28.41% | -17.06% | -30.64% | -116.28% | -139.83% | -156.58% | - |
| EBITDA | -410.73M | -425.07M | -523.98M | -506.31M | -450.59M | -260.96M | -130.27M | -100.78M | -86.41M | -66.56M | -31.05M | -13.08M | -5.22M |
| EBITDA Margin % | -621.45% | -628.14% | -905.33% | -1395.77% | -864.51% | -789.52% | -224.63% | -233.81% | -283.91% | -254.86% | -188.45% | -216.43% | - |
| EBITDA Growth % | 22.62% | 18.88% | -3.49% | -12.37% | -72.67% | -100.32% | -29.26% | -16.64% | -29.81% | -114.33% | -137.41% | -150.52% | - |
| D&A (Non-Cash Add-back) | 9.99M | 15.92M | 10.29M | 8.98M | 7.57M | 6.89M | 6.31M | 5.59M | 4.46M | 2.99M | 1.1M | 328K | 4.5K |
| EBIT | -407.64M | -412.69M | -534.26M | -515.29M | -458.16M | -267.85M | -136.58M | -106.37M | -90.87M | -69.56M | -32.16M | -13.41M | -9.54M |
| Net Interest Income | 25.8M | 29.2M | 47.81M | 49.83M | 8.54M | 1.28M | 2.35M | 6.83M | 5.53M | 2.01M | 525K | 0 | 0 |
| Interest Income | 25.8M | 29.2M | 47.81M | 49.83M | 8.54M | 1.28M | 2.35M | 6.83M | 5.53M | 2.01M | 525K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 26.12M | 28.3M | 15.24M | 34.1M | -16.02M | -42K | 2.35M | 6.83M | 5.53M | 2.01M | 525K | 0 | -9.08M |
| Pretax Income | -394.6M | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M | -99.53M | -85.34M | -67.54M | -31.63M | -13.41M | -14.31M |
| Pretax Margin % | -597.04% | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | -230.92% | -280.42% | -258.62% | -191.97% | -221.86% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.01M | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 7.55% | 0% |
| Net Income | -394.6M | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M | -99.53M | -85.34M | -67.54M | -31.63M | -12.4M | -14.31M |
| Net Margin % | -597.04% | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | -230.92% | -280.42% | -258.62% | -191.97% | -205.11% | - |
| Net Income Growth % | 24.97% | 20.49% | -7.86% | -1.48% | -77.01% | -99.58% | -34.86% | -16.63% | -26.35% | -113.51% | -155.17% | 13.36% | - |
| Net Income (Continuing) | -394.6M | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M | -99.53M | -85.34M | -67.54M | -31.63M | -12.4M | -14.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.33 | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -1.96 | -1.98 | -1.88 | -0.91 | -0.70 | -1.39 |
| EPS Growth % | 32.31% | 27.43% | 3.14% | 12.01% | -62.96% | -57.5% | -22.45% | 1.01% | -5.32% | -106.59% | -30% | 49.64% | - |
| EPS (Basic) | - | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -1.96 | -1.98 | -1.88 | -0.91 | -0.70 | -1.39 |
| Diluted Shares Outstanding | 118.49M | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25M | 43.07M | 36.01M | 34.62M | 17.66M | 10.29M |
| Basic Shares Outstanding | 118.49M | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25M | 43.07M | 36.01M | 34.62M | 17.66M | 10.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
High Cash Burn Rate
As reported in financial statements, Intellia's revenue remains highly erratic, fluctuating between $7.0M and $28.9M over the last ten quarters, reflecting a reliance on non-recurring milestone payments from strategic partners rather than a predictable, scalable commercial product pipeline or consistent organic growth in core therapeutic areas.
The lack of recurring revenue streams suggests that top-line performance is tethered to the timing of clinical milestones rather than market adoption. Investors should monitor whether the company can transition from project-based collaboration inflows to a sustainable commercial model as lead programs advance.
Based on reported figures, Intellia's R&D expenditures consistently dwarf total revenue, with quarterly research costs frequently exceeding $100M, which underscores the significant capital intensity required to advance its in vivo CRISPR/Cas9 platform through the current clinical trial phases without any offsetting commercial product sales.
The company's cost structure is heavily weighted toward clinical development, leaving little room for operational flexibility. This persistent expenditure level suggests that the firm remains entirely dependent on external capital markets to sustain its ongoing research and development activities.
According to recent SEC filings, Intellia's reported net losses are significantly impacted by stock-based compensation, which reached $90.8M in 2025Q4 alone, masking the true underlying cash burn rate and complicating the assessment of management's ability to control operational expenses during this pre-commercial development stage.
The high variability in stock-based compensation suggests that reported earnings may not accurately reflect the company's operational efficiency. Analysts should adjust for these non-cash charges to better understand the actual cash runway and the sustainability of the current R&D-heavy business model.
Based on the provided financial data, the company's cash and equivalents of $155.5M appear insufficient relative to its quarterly operating losses, suggesting that Intellia may face a liquidity crunch that could force dilutive equity financing or a strategic reduction in its clinical development pipeline.
The current cash position warrants close investigation, as the burn rate appears to be accelerating relative to available liquidity. If the company cannot secure additional funding or achieve significant milestone payments, the viability of its long-term clinical programs may be at risk.
Quick answers to the most common questions about buying NTLA stock.
For fiscal year 2025, Intellia Therapeutics, Inc. (NTLA) reported total revenue of $67.7M.
Intellia Therapeutics, Inc. (NTLA) reported a net loss of $412.7M for the fiscal year ending 2025.
Intellia Therapeutics, Inc. (NTLA) reported an operating income of $-441.0M, resulting in an operating profit margin of -651.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Intellia Therapeutics, Inc. (NTLA) generated $51.7M in gross profit for the year, representing a gross profit margin of 76.5%. This demonstrates the company's core pricing power and production efficiency.